Handa Oncology Receives FDA Final Approval for OMCAZIO(TM) (cabozantinib) CapsulesOMCAZIO approved for administration without regard to food, removing strict fasting requirements for cabozantinib patients
Handa Oncology Receives FDA Tentative Approval for OMCAZIO (cabozantinib) CapsulesA novel 505(b)(2) alternate-salt formulation of cabozantinib designed to improve absorption, with no clinically significant food effect
